Argenx Se (ARGX) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Argenx Se  (NASDAQ: ARGX)


Argenx Se's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Argenx Se's ROI in the fourth quarter of 2025?
Argenx Se achieved a return on average invested assets (ROI) of 18.26 % in its fourth quarter of 2025, this is above ARGX's average return on investment of 0.1%.
Argenx Ses investments during the 12 months ending in the fourth quarter of 2025 are valued at $7 billion

ROI has improved compared to 12.61% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 67 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 378.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 35.41 % 35.57 % 36.04 % 36.47 % 37.12 %
Y / Y Net Income Change TTM 55.1 % - - - -
Investment (TTM) in Millions 7,416 7,363 6,159 7,363 5,533
Return On Investment (TTM) 18.26 % 12.61 % 13.55 % 14.66 % 15.94 %
ARGX's Overall Ranking # 378 # 0 # # #
Seq. Investment Change TTM 7.13 % 7.44 % 8.17 % 8.76 % 7.25 %
Seq. Net Income Change TTM 55.1 % 0 % 0 % 0 % -
Net Income (TTM) in Millions 1,292 833 833 833 833

ARGX Company Profile >> Back to ARGX Roi Comparisons >> See Annual ARGX Return On Investment



Return On Investment ARGX's Ranking
Within: No.
Industry # 13
Sector # 68
Overall # 378

Return On Investment Statistics
High Average Low
17.55 %
0.1 %
-25.06 %
(Dec 31 2025)   (Dec 31 2022)







Financial Statements
Argenx Se's IV. Quarter Investments $ 7,416 Millions ARGX's Balance sheet
Argenx Se's IV. Quarter Income $ 1,292 Millions Quarterly ARGX's Income Statement
ARGX's Income by Division See ARGX's Income by Division


ARGX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 7,363 5,533 4,119 2,832 2,549
Y / Y Investment Growth 33.07 % 34.3 % 45.46 % 11.1 % 34.25 %
Net Income in Millions 1,292 833 -295 -710 -408
Y / Y Net Income Growth 55.1 % - - - -
Annual Return On Investment 17.55 % 15.06 % -7.16 % -25.06 % -16.02 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 17.55 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ARGX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ARGX's Competitors
Subscribers only: Roi for Argenx Se's Suppliers
Subscribers only: Return On Investment for ARGX's Customers

Other Ratios
ARGX's Roa ARGX's Inventory Turnover Ratio ARGX's Growth Rates ARGX's Dividend Statistics
ARGX's Profitability Ratios ARGX's Asset Turnover Ratio ARGX's Dividend Growth
ARGX's Roe ARGX's Valuation Ratios ARGX's Financial Strength Ratios ARGX's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Gsk Plc  44.94 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %
Incyte Corporation  27.08 %
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %
Puma Biotechnology Inc   25.39 %
Catalyst Pharmaceuticals Inc   24.25 %
Iradimed Corporation  22.97 %
Innoviva Inc   22.62 %

Date modified: 2026-07-07T09:15:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.